Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXP · Real-Time Price · USD
0.139
+0.013 (10.63%)
At close: Oct 4, 2024, 4:00 PM
0.140
+0.001 (0.43%)
After-hours: Oct 4, 2024, 7:58 PM EDT
TNXP Revenue
Tonix Pharmaceuticals Holding had revenue of $2.21M in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $12.46M. In the year 2023, Tonix Pharmaceuticals Holding had annual revenue of $7.77M.
Revenue (ttm)
$12.46M
Revenue Growth
n/a
P/S Ratio
0.02
Revenue / Employee
$120,951
Employees
103
Market Cap
19.51M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cumberland Pharmaceuticals | 37.79M |
Apollomics | 2.10M |
Beyond Air | 1.78M |
GeoVax Labs | 300.68K |
Evaxion Biotech | 278.00K |
TNXP News
- 4 days ago - The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions - Accesswire
- 8 days ago - Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines - GlobeNewsWire
- 16 days ago - Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines - GlobeNewsWire
- 17 days ago - New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution - Accesswire
- 19 days ago - Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency - GlobeNewsWire
- 25 days ago - Penny stocks analysis: AITX, Intelligent Bio (INBS), Tonix (TNXP) - Invezz
- 4 weeks ago - Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek - GlobeNewsWire
- 4 weeks ago - As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL - Accesswire